Results 191 to 200 of about 174,681 (296)

Use of the PROMIS and Neuro‐QoL to Evaluate Health‐Related Quality of Life following Unilateral Subthalamic Deep Brain Stimulation for Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Subthalamic nucleus deep brain stimulation (STN DBS) improves Parkinson's disease (PD)‐related motor symptoms, but how STN DBS impacts various aspects of patient‐perceived health‐related quality of life (HRQoL) is less clear. The Patient‐Reported Outcome Measurement Instrument (PROMIS) and Quality of Life in Neurological Disorders ...
Sarah A. Brinkerhoff   +10 more
wiley   +1 more source

Recent Advances in Exosome‐Based Nanodelivery Systems for Traumatic Brain Injury Treatment

open access: yesMed Research, EarlyView.
An overview of functional modification, therapeutic effects, molecular composition, and delivery strategies for exosomes. ABSTRACT Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability.
Jue Zhu   +9 more
wiley   +1 more source

Integrative Multi‐Omics Analysis Reveals Convergent Epigenome and Transcriptome Changes in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background The mechanisms that predispose dopaminergic neurons (DAN) to degeneration in Parkinson's disease (PD) are incompletely understood. Objective To perform an integrative multi‐omics reanalysis of single‐cell transcriptomic and epigenomic data to identify convergent alterations predisposing dopaminergic neurons to degeneration in ...
Mirco Macchi   +127 more
wiley   +1 more source

Favorable outcome of engraftment of custom designed RADA16-I based hydrogels functionalized with SDF1 or IL4 mimicking peptides to injured or dystrophic muscles. [PDF]

open access: yesSci Rep
Ostaszewska A   +19 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy